The therapeutic community is excited with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 agonist that’s showing significant promise in clinical trials for addressing obesity. Unlike some available weight loss approaches, retatrutide appears to deliver a greater substantial reduction in body size and improve metabolic marker